Paver Elizabeth C, Morey Adrienne L
Department of Anatomical Pathology, The Canberra Hospital, Canberra, ACT, Australia; Australian National University, Canberra, ACT, Australia.
Department of Anatomical Pathology, The Canberra Hospital, Canberra, ACT, Australia; Australian National University, Canberra, ACT, Australia.
Pathology. 2024 Mar;56(2):147-157. doi: 10.1016/j.pathol.2023.11.002. Epub 2023 Dec 12.
Biomarkers are central to the delivery of personalised/precision medicine and are increasingly used across all areas of medicine to improve diagnostic accuracy, determine prognosis and predict response to treatment. Biomarkers can be used to develop assays that are then further developed into diagnostic tests, or in vitro diagnostic devices, which require an exhaustive validation and approval process. Pathologists play a critical role in the ordering and interpretation of biomarker assays. However, the evolution of a new biomarker from discovery to clinical implementation is complex, subject to various levels of scientific, clinical and regulatory scrutiny, with an approval process that varies significantly between jurisdictions. Therefore, it is important that pathologists have a solid understanding of how biomarkers are developed, the process of biomarker validation, how new biomarkers are approved for clinical use and the potential issues around implementation of biomarker testing that may lead to inaccurate results. This paper aims to provide an overview of the process of biomarker development, approval and validation, and practical tips for anatomical pathologists involved in the testing of biomarkers in routine practice.
生物标志物是个性化/精准医疗的核心,在医学各个领域的应用日益广泛,以提高诊断准确性、确定预后并预测治疗反应。生物标志物可用于开发检测方法,进而发展为诊断测试或体外诊断设备,这需要详尽的验证和审批过程。病理学家在生物标志物检测的订购和解读中发挥着关键作用。然而,一种新的生物标志物从发现到临床应用的演变过程很复杂,要经过不同层面的科学、临床和监管审查,且审批流程在不同司法管辖区差异很大。因此,病理学家必须扎实了解生物标志物的开发方式、验证过程、新生物标志物获批临床使用的流程以及生物标志物检测实施过程中可能导致结果不准确的潜在问题,这很重要。本文旨在概述生物标志物的开发、审批和验证过程,并为在日常实践中参与生物标志物检测的解剖病理学家提供实用建议。